Phantom Neuro Showcases Minimally Invasive Neurotech Approach With Phantom X

A LinkedIn post from Phantom Neuro highlights a discussion between Founder & CEO Connor Glass and Ashlee Vance about the company’s Phantom X system. The post indicates that Phantom X is designed to capture electrical signals from the body, implanted under the skin in the limb rather than using invasive brain-computer interface surgery.

According to the post, this approach seeks to leverage intact neural pathways in individuals with limb loss, enabling users’ intent to control external devices. The system is described as focusing on larger, more stable signals from the body, which the post suggests could support a more scalable interface across multiple applications.

For investors, this content points to Phantom Neuro’s positioning within the neurotechnology and human–machine interface segments, with potential relevance to medtech and defense innovation markets. If the technology proves clinically effective and scalable, it could open recurring revenue opportunities in prosthetics control, rehabilitation devices, and possibly defense-related interfaces.

The emphasis on avoiding brain surgery may lower adoption barriers relative to fully invasive brain-computer interfaces, potentially expanding the addressable patient population and partner interest. However, investors would need independent validation on regulatory progress, reimbursement prospects, and integration with device manufacturers to assess commercialization timelines and revenue visibility.